OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
Better coordination in development and review of vaccines is needed.
Advances in technology are accelerating the development and manufacture of subunit vaccines.
Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.
May 18, 2022
Pfizer and BioNTech’s COVID-19 vaccine has been granted EUA for booster doses in children five through 11 years of age.
The companies have reached an agreement with the European Commission to update their COVID-19 vaccine supply agreement.
May 06, 2022
FDA is limiting the use of Janssen’s COVID-19 vaccine to certain individuals.
May 03, 2022
FDA’s Office of Compliance has released its 2021 Annual Report, which highlights the agency’s successes in public health.
May 02, 2022
Moderna has filed for emergency use authorization of its COVID-19 vaccine for use in young children six months to under six years of age.
April 25, 2022
FDA has approved Veklury to treat COVID-19 in pediatric patients under 12 years of age.
April 14, 2022
ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.
April 13, 2022
Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland.
April 12, 2022
Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine for treatment of COVID-19.
April 08, 2022
FDA has granted Priority Review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.